m+Medelevator.RU
← Поиск публикаций
Drugs in R&D · 2025

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Murrell Derek E, Kennard Benjamin C, Bertoni Maria E, Cluck David B, Moorman Jonathan P, Brown Stacy D, Wang Kesheng, Duffourc Michelle M, Harirforoosh Sam

Аннотация

BACKGROUND AND OBJECTIVES: The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy and tolerability among patients. This study sought to investigate the relationship, if any, of single nucleotide polymorphisms (SNPs) and selected clinical parameters.

METHODS: The study population, predominantly Caucasian males with a median age of 53.0 years [interquartile range 46.0-59.0], was assayed for genetic variations using an iPLEX ADME PGx Pro v1.0 Panel.

RESULTS: Although several SNP relationships were found with both forms of tenofovir, many of the reported SNPs were displayed only in the comprehensive regimen grouping, making it difficult to distinguish between the two prodrug forms.

CONCLUSIONS: Being an exploratory study, the findings of this substudy serve as potential avenues for further research.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты